Management of immunosuppression in the treatment of chronic lymphocytic leukemia
暂无分享,去创建一个
[1] R. Greil,et al. Mimicking the microenvironment in chronic lymphocytic leukaemia – where does the journey go? , 2013, British Journal of Haematology.
[2] C. Croce,et al. The Nature of the Antigen Determines Leukemia Development and Behavior in the Eμ-TCL1 Transgenic Mouse Model of CLL , 2012 .
[3] V. Vullo,et al. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. , 2011, World journal of gastroenterology.
[4] Celine M Vachon,et al. Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. , 2011, Blood.
[5] A. Berrebi,et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.
[6] V. Morrison. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. , 2010, Best practice & research. Clinical haematology.
[7] L. Pleyer,et al. Molecular and cellular mechanisms of CLL: novel therapeutic approaches , 2009, Nature Reviews Clinical Oncology.
[8] J. Gribben,et al. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab , 2009, Annals of Hematology.
[9] Thomas F. Smith,et al. Quantitative real-time polymerase chain reaction for evaluating DNAemia due to cytomegalovirus, Epstein-Barr virus, and BK virus in solid-organ transplant recipients. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] M. Grever,et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Keating,et al. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. , 2006, Clinical lymphoma & myeloma.
[12] R. Greil,et al. Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. , 2006, Cancer treatment reviews.
[13] H. Einsele,et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] G. Brittinger,et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. , 2005, Blood.
[15] P. Chiusolo,et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. , 2004, Haematologica.
[16] R. Rosenquist,et al. Similar Humoral Immunity Parameters in Chronic Lymphocytic Leukemia Patients Independent of VH Gene Mutation Status , 2004, Leukemia and Lymphoma.
[17] M. Sinisalo,et al. Vaccination Against Infections in Chronic Lymphocytic Leukemia , 2003, Leukemia & lymphoma.
[18] A. Hartkamp,et al. Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. , 2001, Vaccine.
[19] M. Grever,et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. , 2000, Blood.
[20] S. Molica,et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. , 1996, Haematologica.
[21] A. Randomized. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. , 1988 .